Market Research Logo

Japan Pharmaceuticals and Healthcare Report Q2 2016

Japan Pharmaceuticals and Healthcare Report Q2 2016

BMI View: Japanese pharmaceutical firms will be forced to adapt their business model to accommodate thechanging domestic medicine landscape. With the market share of generic drugs expected to grow in linewith government incentives, Japan-based drugmakers will see revenues from long-listed products comeunder increasing pressure. For research-based firms, innovation will become the key to navigate thisbusiness environment which necessitates a focus on core competencies.

Headline Expenditure Projections

Pharmaceuticals: JPY11.5trn (USD94.9bn) in 2015 to JPY11.7trn (USD101.6bn) by 2016 with a y-o-ygrowth of 2.2% in local currency terms and -7.1% in USD terms.

Healthcare: JPY51.3trn (USD432.8bn) in 2015 to JPY52.3trn (USD439.7bn) in 2016 with a y-o-ygrowth of 2.0% in local currency terms and 1.6% in USD terms. Healthcare spending revised downwardsdue to new data from the World Health Organization. The lower US dollar amount is driven by theweakening of the yen against the dollar.


BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Japan 2014-2020)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Japan 2012-2020)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Japan 2012-2020)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Japan 2012-2020)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Japan 2012-2020)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Japan 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Japan 2014-2020)
Industry Risk Reward Index
Asia Pacific Risk/Reward Index
Japan Risk/Reward Index
Rewards
Risks
Regulatory Review
Regulatory Development
Table: Re-examination Period
Pricing & Reimbursement
Market Overview
Healthcare Sector
Table: Healthcare Resources (Japan 2010-2015)
Table: Healthcare Personnel (Japan 2010-2015)
Table: Healthcare Activity (Japan 2010-2015)
Research & Development
Clinical Trials
Epidemiology
Table: Estimated Number Of New Cases Of Cancer In Japan
Table: Japan: Dementia Cases And Types Across Different Areas
Competitive Landscape
Research-Based Industry
Table: Companies Represented By The JPMA
Table: Multinational Pharmaceutical Firm Activity
Generic Drug Industry
Table: Members Of The Japan Generic Medicines Association
Pharmaceutical Distribution
Pharmaceutical Retail Sector
Company Profile
Astellas
AstraZeneca
Daiichi Sankyo
Eisai
GlaxoSmithKline
Merck & Co
Mitsubishi Tanabe
Novartis
Pfizer
Sanofi
Sawai Pharmaceutical
Takeda Pharmaceutical Company
Demographic Forecast
Demographic Outlook
Table: Population Headline Indicators (Japan 1990-2025)
Table: Key Population Ratios (Japan 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Japan 1990-2025)
Table: Population By Age Group (Japan 1990-2025)
Table: Population By Age Group % (Japan 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report